Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Neuroendocrine Tumors 1Hypoxia 1HCC 1Carcinoma, Hepatocellular 1

Interventions

lutetium Lu 177 dotatate 10Everolimus 5lanreotide 4gallium Ga 68 dotatate 4Nivolumab 4Magnetic Resonance Spectroscopy 4177Lu-octreotide, DOTA(0)-Tyr(3)- 4olaparib 3Temozolomide 3Somatostatin 3Capecitabine 3surufatinib 2pembrolizumab 2copper dotatate CU-64 2cabozantinib 2amino-acid, glucose, and electrolyte solution 2Specimen Handling 2Octreotide 2Lutetium-177 2Lutetium 2Injections 2Fluorodeoxyglucose F18 2Cyclophosphamide 2tivozanib 1talazoparib 1sintilimab 1repotrectinib 1lenvatinib 1guarana powder 1gadoteridol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Neuroendocrine Tumors × Tirapazamine × Clear all
NCT02174549 2026-04-20

Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Teclison Ltd.

Phase 1/2 Recruiting
25 enrolled
EndocrineGastrointestinalNET

Hypoxia, Carcinoma, Hepatocellular, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡